Sugi Predict

Sugi Predict / Compounds / Propionyl-Carnitine

Propionyl-Carnitine

Propionyl-Carnitine

SCHEMBL4279796

CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C.CN(CC(=O)O)C(=N)N

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.65
▸ KMT2A Q03164 5/20 0.65
▸ CYP2C19 P33261 2/20 0.65
▸ RECQL P46063 1/20 0.65
▸ MAPT P10636 4/20 0.48
▸ SLC25A20 O43772 3/20 0.48
▸ TP53 P04637 3/20 0.48
▸ TSHR P16473 3/20 0.48
▸ CYP2D6 P10635 2/20 0.48
▸ SLC6A5 Q9Y345 2/20 0.48
▸ CYP2C9 P11712 2/20 0.48
▸ HIF1A Q16665 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ NFKB1 P19838 1/20 0.48
▸ THPO P40225 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ CYP1A2 P05177 4/20 0.47
▸ HRH1 P35367 1/20 0.47
▸ MAPK1 P28482 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Propionyl-Carnitine SCHEMBL27583438 0.99 MEN1 (0.64) MEN1KMT2ACYP2C19RECQLMAPT
Propionyl-Carnitine SCHEMBL27583440 0.96 MEN1 (0.60) MEN1KMT2ACYP2C19RECQLMAPT
Creatine SCHEMBL15322407 0.84 MEN1 (0.45) MEN1KMT2ACYP2C19RECQLMAPT
Creatine SCHEMBL5423002 0.83 MEN1 (0.44) MEN1KMT2ACYP2C19RECQLMAPT
Creatine SCHEMBL5423005 0.83 MEN1 (0.44) MEN1KMT2ACYP2C19RECQLMAPT
Propionyl-Carnitine SCHEMBL19617435 0.82 MEN1 (0.90) MEN1KMT2ACYP2C19RECQLMAPT
Hydrochloric Acid SCHEMBL27583437 0.82 MEN1 (0.51) MEN1KMT2ACYP2C19RECQLMAPT
Creatine SCHEMBL5422993 0.81 MEN1 (0.41) MEN1KMT2ACYP2C19RECQLMAPT
Creatine SCHEMBL5422996 0.81 MEN1 (0.41) MEN1KMT2ACYP2C19RECQLMAPT
SCHEMBL28018108 0.81 LMNA (0.51) MEN1KMT2ACYP2C19RECQLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2567705-A2 Methods of treating cognitive dysfunction by modulating brain energy metabolism Avicena Group, Inc. (US) 2013-03-13 — — EP claimed
US-20060241021-A1 Methods of treating cognitive dysfunction by modulating brain energy metabolism UNIVERSITY OF CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2006-10-26 — — US claimed
EP-1567180-A2 METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM Avicena Group, Inc. (US) 2005-08-31 — — EP claimed
US-20040126366-A1 Methods of treating cognitive dysfunction by modulating brain energy metabolism CINCINNATI, UNIVERSITY OF 2004-07-01 — — US claimed
WO-2003101402-A2 METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM AVICENA GROUP, INC. (US) 2003-12-11 — — WO claimed
EP-2567705-A2 Methods of treating cognitive dysfunction by modulating brain energy metabolism Avicena Group, Inc. (US) 2013-03-13 — — EP disclosed
US-20120245211-A1 Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2012-09-27 — — US disclosed
US-20090221706-A1 Methods of treating cognitive dysfunction by modulating brain energy metabolism UNIVERSITY OF CINCINNATI 2009-09-03 — — US disclosed
US-20070027090-A1 Methods of treating cognitive dysfunction by modulating brain energy metabolism UNIVERSITY OF CINCINNATI 2007-02-01 — — US disclosed
US-20060241021-A1 Methods of treating cognitive dysfunction by modulating brain energy metabolism UNIVERSITY OF CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2006-10-26 — — US disclosed
EP-1567180-A2 METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM Avicena Group, Inc. (US) 2005-08-31 — — EP disclosed
US-20040126366-A1 Methods of treating cognitive dysfunction by modulating brain energy metabolism CINCINNATI, UNIVERSITY OF 2004-07-01 — — US disclosed
WO-2003101402-A2 METHODS OF TREATING COGNITIVE DYSFUNCTION BY MODULATING BRAIN ENERGY METABOLISM AVICENA GROUP, INC. (US) 2003-12-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027090-A1 Methods of treating cognitive dysfunction by modulating brain energy metabolism PC, PYGB, PCK2 MEN1 3865/4885KMT2A 2492/4885CYP2C19 2983/4885
US-20060241021-A1 Methods of treating cognitive dysfunction by modulating brain energy metabolism PC, PYGB, PCK2 MEN1 3865/4885KMT2A 2492/4885CYP2C19 2983/4885
US-20120245211-A1 Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism PC, PYGB, PCK2 MEN1 3865/4885KMT2A 2492/4885CYP2C19 2983/4885
US-20040126366-A1 Methods of treating cognitive dysfunction by modulating brain energy metabolism PC, PYGB, PCK2 MEN1 3865/4885KMT2A 2492/4885CYP2C19 2983/4885
US-20090221706-A1 Methods of treating cognitive dysfunction by modulating brain energy metabolism PC, PYGB, PCK2 MEN1 3865/4885KMT2A 2492/4885CYP2C19 2983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.